Sign In
Buy LLY
$1,185.71
-7.09 (-0.594%)
At Close: Aug 07, 2026
Eli Lilly Alzheimer's drug to be blocked for use by NHS, The Telegraph reports
05:18pm, Friday, 23'rd Aug 2024
Eli Lilly's treatment for early Alzheimer's is expected to be blocked for use by Britain's National Health Service (NHS), The Telegraph reported on Friday.
Stock Market This Week: Powell Fuels Rally, TGT Flexes Retail Strength, LLY Drug Trial Success
05:12pm, Friday, 23'rd Aug 2024
A back-and-forth week in the markets turned to the upside when Fed Chair Jerome Powell shared optimism during his speech at Jackson Hole. Target (TGT) led the charge in retail strength, while Eli Lill
These Were the Top-Selling GLP-1 Drugs Last Quarter From Eli Lilly and Novo Nordisk
08:00am, Friday, 23'rd Aug 2024
Eli Lilly and Novo Nordisk's top diabetes drugs each brought in more than $3 billion in sales last quarter. Ozempic has been on the market for longer, but its growth rate isn't as impressive as that o
Lilly to participate in Morgan Stanley 22nd Annual Global Healthcare Conference
10:00am, Thursday, 22'nd Aug 2024
INDIANAPOLIS , Aug. 22, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley 22nd Annual Global Healthcare Conference on Sept. 5, 2024. Jacob Van Naarden, executive vi
Eli Lilly's Growth Rate Is Fantastic, but This Number Is Even Better
06:45am, Thursday, 22'nd Aug 2024
Eli Lilly's sales rose by 36% last quarter to $11.3 billion. The company's low cost of sales has boosted its bottom line at a much higher rate.
This Undervalued Stock Could Join the Race With Eli Lilly to the $1 Trillion Club
06:17am, Thursday, 22'nd Aug 2024
Eli Lilly's weight loss drugs are pushing the company's market cap toward $1 trillion. Johnson & Johnson is the global leader in drug sales, but its market cap is under $400 billion.
The Big 3: LULU, LLY & SMCI
12:50pm, Wednesday, 21'st Aug 2024
Lululemon (LULU) gains off recent retail strength, Eli Lilly (LLY) shows dominance after recent success in drug trials, and Supermicro (SMCI) attempts to hold onto a recent bounce-back. Don Kaufman wi
Lilly (LLY) Up 3% on Obesity Drug Cutting Diabetes Risk
11:41am, Wednesday, 21'st Aug 2024
Eli Lilly (LLY) reports data from a late-stage study that found that long-term treatment with Zepbound reduces the risk of progression to type 2 diabetes by 94%.
Novo Nordisk Vs. Eli Lilly: Beyond The Weight-Loss Drug Battle
08:51am, Wednesday, 21'st Aug 2024
The rivalry between Novo Nordisk A/S NVO and Eli Lilly and Co LLY has heated up as both companies vie for dominance in the booming obesity-drug market. But for investors, the real story may lie beyond
Watch These Eli Lilly Price Levels as Stock Sets Record High on Trial Results
08:06am, Wednesday, 21'st Aug 2024
Eli Lilly (LLY) shares set a record high on Tuesday after announcing that clinical trials of tirzepatide, the medicine used in the company's diabetes drug Mounjaro and injectable weight loss treatment
Eli Lilly Stock Could Soar to $1,150, According to a Wall Street Analyst. Is It a Buy at Around $945?
04:36am, Wednesday, 21'st Aug 2024
Bank of America's price target for Eli Lilly implies a gain of about 25% from the stock's recent closing price. Eli Lilly's blockbuster weight management drug is gaining market share at a rapid pace.
Eli Lilly's Zepbound reduces type 2 diabetes risk, study shows
07:07pm, Tuesday, 20'th Aug 2024
Eli Lilly announced results of a study in which weekly shots of tirzepatide injections significantly reduced the risk of progression to type 2 diabetes by 94% among certain adults.
Eli Lilly stock gains on weight loss drug that cuts Type 2 diabetes risk by 94%
06:58pm, Tuesday, 20'th Aug 2024
Shares of Eli Lilly are moving higher on Tuesday after the company revealed that a recent study, conducted by the company, showed that its weight-loss drug tirzepatide, the active ingredient in its we
Eli Lilly's Zepbound may be best-in-breed for weight loss drugs, says Dr. Kavita Patel
06:43pm, Tuesday, 20'th Aug 2024
Dr. Kavita Patel joins 'Fast Money' to talk Eli Lilly's GLP-1 entrant cutting diabetes risk, the weight-loss drugs sector as a whole, and more.
Why Eli Lilly Topped the Market on Tuesday
04:46pm, Tuesday, 20'th Aug 2024
The pharmaceutical giant has been investigating its Zepbound/Mounjaro drug for various indications. It performed very well in its latest diabetes and weight loss study.
